A study of an injected virus for advanced solid tumors
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new treatment where a virus (GC001) is injected directly into a tumor. The virus is designed to attack cancer cells and may help people with advanced solid tumors that haven't responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have an advanced solid tumor (like colorectal, lung, ovarian, or cervical cancer) that has not responded to standard treatments or for which no standard treatment exists.
- You must have at least one tumor that can be easily reached with a needle for injection, as seen on a scan.
- You must be in good enough health to carry out daily activities (ECOG score 0 or 1).
- Your blood counts, liver, kidney, and heart function must be within certain acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental virus therapy called VSV-02 for people with advanced solid tumors that have not responded to standard treatments. The treatment is given directly into a tumor, aiming to attack cancer from the inside.
This early-phase trial tests an injection of a virus designed to attack cancer cells in people with advanced solid tumors. It is meant for situations where standard treatments have not worked (or you can’t/won’t take them) and when doctors can directly deliver the treatment to a tumor spot.
This trial tests a new virus-based therapy (VG161) injected directly into tumors for people with advanced bone and soft tissue sarcoma that hasn't responded to other treatments. The goal is to see if the virus can shrink tumors and slow the cancer's growth.
This trial tests a modified virus injected directly into tumors to treat metastatic gastrointestinal and peritoneal cancers. It aims to see if this approach can shrink tumors or slow their growth.
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
This study tests a new combination treatment: a modified virus (hV01) injected directly into a tumor, plus a drug that helps your immune system attack cancer cells (PD-1 inhibitor). It is for people with advanced solid tumors that have not responded to standard therapies.
Hear when a new Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.